Raphas Co. Ltd - Asset Resilience Ratio

Latest as of March 2026: 16.43%

Raphas Co. Ltd (214260) has an Asset Resilience Ratio of 16.43% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩11.87 Billion

≈ $8.05 Million USD Cash + Short-term Investments

Total Assets

₩72.26 Billion

≈ $48.97 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Raphas Co. Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Raphas Co. Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Raphas Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 214260 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩11.87 Billion	16.43%
Total Liquid Assets	₩11.87 Billion	16.43%

Asset Resilience Insights

Good Liquidity Position: Raphas Co. Ltd maintains a healthy 16.43% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Raphas Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Raphas Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Raphas Co. Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Raphas Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	13.15%	₩9.88 Billion ≈ $6.69 Million	₩75.08 Billion ≈ $50.88 Million	+3.49pp
2024-12-31	9.66%	₩7.35 Billion ≈ $4.98 Million	₩76.09 Billion ≈ $51.57 Million	-12.02pp
2023-12-31	21.69%	₩21.78 Billion ≈ $14.76 Million	₩100.40 Billion ≈ $68.04 Million	-11.09pp
2022-12-31	32.78%	₩31.49 Billion ≈ $21.34 Million	₩96.06 Billion ≈ $65.10 Million	-13.44pp
2021-12-31	46.22%	₩45.22 Billion ≈ $30.65 Million	₩97.84 Billion ≈ $66.31 Million	+22.39pp
2020-12-31	23.83%	₩14.25 Billion ≈ $9.66 Million	₩59.83 Billion ≈ $40.54 Million	-2.48pp
2019-12-31	26.30%	₩16.54 Billion ≈ $11.21 Million	₩62.88 Billion ≈ $42.62 Million	+12.85pp
2018-12-31	13.45%	₩4.64 Billion ≈ $3.15 Million	₩34.51 Billion ≈ $23.39 Million	-15.59pp
2017-12-31	29.04%	₩10.11 Billion ≈ $6.85 Million	₩34.81 Billion ≈ $23.59 Million	--

pp = percentage points

About Raphas Co. Ltd

KQ:214260 Korea Biotechnology

Market Cap

$50.26 Million

₩74.16 Billion KRW

Market Cap Rank

#21826 Global

#1290 in Korea

Share Price

₩8820.00

Change (1 day)

+6.78%

52-Week Range

₩6720.00 - ₩15500.00

All Time High

₩75400.00